Tuan Tran
About Tuan Tran
Tuan Tran, age 51, serves as Chief Operating Officer (COO) of Marwynn Holdings, Inc. since April 1, 2024; he is also COO of subsidiary FuAn Enterprise since October 1, 2023 . He holds a BS in Public Health from Southern Connecticut State University and certifications in Pharmaceutical Engineering, Six Sigma Green Belt, Food Safety, Technical Writing, and HACCP; he is a senior member of the American Society for Quality . Tran brings 20+ years of operations and quality experience across nutrition, dietary supplements, and OTC industries, with responsibilities spanning production, warehousing, quality, customer service, R&D, procurement, HR, and safety; his expertise includes FDA regulations, GMPs, HACCP, CAPA, Lean Manufacturing, and crisis/regulatory compliance . Company performance context: FY2024 revenue increased YoY and EBITDA rose YoY; see table below for detail and S&P Global data caveat.
Company Performance (during tenure context)
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenue ($) | $11,255,456* | $11,920,570 |
| EBITDA ($) | $1,113,610* | $1,510,658* |
*Values retrieved from S&P Global.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| FuAn Enterprise (subsidiary) | Chief Operating Officer | Oct 2023 – present | Oversight of day-to-day administrative and operational functions |
| Bio Essence Corporation | Chief Operating Officer | 2018 – 2023 | Led operations leadership prior to joining FuAn; industry experience in nutrition/dietary supplements/OTC |
| AMF Pharma | Chief Operating Officer | Not disclosed | Operations leadership; regulatory and quality systems know-how |
| Harmony Health Labs | General Manager | Not disclosed | Operations management across production/quality |
| SK Laboratories | VP of Operations | Not disclosed | Operations and quality leadership |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| American Society for Quality | Senior Member | Not disclosed | Professional quality/operations affiliation |
Fixed Compensation
| Component | FY 2024 | FY 2025 |
|---|---|---|
| Base Salary ($) | $58,334 | $100,000 |
| Target Bonus (%) | — | — |
| Actual Bonus Paid ($) | — | — |
| Stock Awards ($) | — | — |
| Option Awards ($) | — | — |
| All Other Compensation ($) | — | — |
| Total ($) | $58,334 | $100,000 |
| Notes | Paid by FuAn (subsidiary) | Paid by FuAn (subsidiary) |
Performance Compensation
- No RSUs, PSUs, or option awards were outstanding for named executive officers (including Tuan Tran) as of April 30, 2025 .
- The 2024 Amended and Restated Equity Incentive Plan authorizes 93,000 shares; as of the proxy date, options were granted to independent directors, not executive officers .
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| None disclosed for Tuan Tran | — | — | — | — | — |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial Ownership (shares) | Tuan Tran is not individually listed in the beneficial ownership table; officers/directors shown do not include a line for Tran . |
| Vested vs Unvested Shares | No outstanding equity incentive awards for named executive officers as of April 30, 2025 . |
| Options (exercisable/unexercisable) | None outstanding as of April 30, 2025 . |
| Shares Pledged as Collateral | Not disclosed in proxy; company outlines insider trading policy and potential use of Rule 10b5-1 plans generally . |
| Stock Ownership Guidelines | Not disclosed. |
| Compliance Status with Guidelines | Not disclosed. |
Employment Terms
| Term | Provision |
|---|---|
| Employment Start (COO) | April 1, 2024 |
| Executive Officer Since | 2024 |
| Contract/Agreement | No employment or consulting agreements with executive officers |
| Salary | $100,000 per year for COO |
| Severance | Not disclosed |
| Change-of-Control | Not disclosed |
| Clawback Policy | Adopted; company may recoup incentive compensation from covered executives upon accounting restatement (Section 10D/Nasdaq rules) |
| Insider Trading Policy | Adopted; Rule 10b5-1 plans permitted; policies designed to ensure compliance |
| Indemnification | Standard indemnification agreements executed with executive officers and board members |
| Pension/SERP | None; no pension, retirement, or similar benefits for executive officers |
| Non-Compete/Non-Solicit/Garden Leave | Not disclosed. |
Investment Implications
- Pay-for-performance alignment appears limited: Tran’s compensation is primarily fixed cash with no disclosed annual bonus payouts and no outstanding equity awards, reducing direct linkage to shareholder returns . The absence of performance-based equity may lessen alignment and retention incentives relative to peers .
- Governance mitigants exist: Company has adopted insider trading and clawback policies, and standard indemnification agreements; policies allow 10b5-1 trading plans and enable recovery of incentive compensation upon restatement .
- Retention risk: No employment agreement, severance, or change-of-control protections are disclosed for Tran, potentially increasing portability; salary is paid via subsidiary FuAn, indicating operating alignment but not equity-based retention .
- Execution backdrop: Tran’s deep regulatory/quality and operations background (FDA/GMP/HACCP/CAPA/Lean) supports operational reliability; however, the lack of disclosed performance incentives means operational success may not directly translate into incentive pay outcomes .
- Company performance context: FY2024 revenue and EBITDA grew YoY, indicating improving operating scale; but compensation design does not directly tie Tran’s pay to revenue/EBITDA metrics based on disclosures * .
*Values retrieved from S&P Global.